帯状ヘルペス(シングルス)(Herpes Zoster (Shingles)):治療薬開発パイプライン動向(2015年上半期版)

Global Markets Directが発行した調査報告書(GMDHC6433IDB)
◆英語タイトル:Herpes Zoster (Shingles) - Pipeline Review, H1 2015
◆商品コード:GMDHC6433IDB
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2015年3月19日
◆ページ数:61
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥226,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥452,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥678,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Global Markets Direct社の概要及び新刊レポートはこちらでご確認いただけます。

当調査レポートでは、世界における帯状ヘルペス(シングルス)(Herpes Zoster (Shingles))の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。

・イントロダクション
・帯状ヘルペス(シングルス)(Herpes Zoster (Shingles))の概要
・帯状ヘルペス(シングルス)(Herpes Zoster (Shingles))治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・帯状ヘルペス(シングルス)(Herpes Zoster (Shingles))パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・製品
・大学/研究機関別、研究中の製品
・帯状ヘルペス(シングルス)(Herpes Zoster (Shingles))治療薬開発に取り組んでいる企業:企業別製品パイプライン
・帯状ヘルペス(シングルス)(Herpes Zoster (Shingles))治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Herpes Zoster (Shingles) – Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Herpes Zoster (Shingles) – Pipeline Review, H1 2015’, provides an overview of the Herpes Zoster (Shingles)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Herpes Zoster (Shingles), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Herpes Zoster (Shingles) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Herpes Zoster (Shingles)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Herpes Zoster (Shingles) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Herpes Zoster (Shingles) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Herpes Zoster (Shingles) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Herpes Zoster (Shingles)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Herpes Zoster (Shingles) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Herpes Zoster (Shingles) Overview 7
Therapeutics Development 8
Pipeline Products for Herpes Zoster (Shingles) – Overview 8
Pipeline Products for Herpes Zoster (Shingles) – Comparative Analysis 9
Herpes Zoster (Shingles) – Therapeutics under Development by Companies 10
Herpes Zoster (Shingles) – Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Unknown Stage Products 14
Herpes Zoster (Shingles) – Products under Development by Companies 15
Herpes Zoster (Shingles) – Companies Involved in Therapeutics Development 16
Astellas Pharma Inc. 16
Epiphany Biosciences, Inc. 17
Foamix Pharmaceuticals Ltd. 18
GlaxoSmithKline plc 19
Merck & Co., Inc. 20
NAL Pharmaceuticals Ltd. 21
Spider Biotech 22
Herpes Zoster (Shingles) – Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Target 24
Assessment by Mechanism of Action 26
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles 32
acyclovir – Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
amenamevir – Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
FV-100 – Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
GSK-1437173A – Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
NAL-3221 – Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
NAL-3223 – Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
SB105-A10 – Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
V-212 – Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
valomaciclovir stearate – Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Herpes Zoster (Shingles) – Recent Pipeline Updates 46
Herpes Zoster (Shingles) – Dormant Projects 50
Herpes Zoster (Shingles) – Discontinued Products 51
Herpes Zoster (Shingles) – Product Development Milestones 52
Featured News & Press Releases 52
Mar 09, 2015: ContraVir Pharmaceuticals to Initiate Pivotal Phase 3 Study of FV-100 for Prevention of Shingles-Associated PHN 52
Dec 18, 2014: Pivotal phase III study of GSK shingles candidate vaccine meets its primary endpoint 52
Dec 18, 2014: Positive Outcome of Phase 3 Study of GSK Shingles Vaccine Containing Agenus Adjuvant 53
Dec 09, 2014: ContraVir Pharmaceuticals Initiates Pharmacokinetic Study of Lead Antiviral FV-100 for Treating Shingles 53
Oct 16, 2014: ContraVir Pharmaceuticals Selects Pharmaceutical Product Development to Manage Phase 2b Study of Lead Antiviral FV-100 for Treating Shingles 54
Apr 09, 2013: Zoster Vaccine Effective Against Incident Herpes Zoster And Post-herpetic Neuralgia In Older US Population, Cohort Study Finds 54
Jul 18, 2012: Agenus Annnounces Intiation Of Phase III Clinical Trial Of GSK’s Herpes Zoster Vaccine Candidate In Immunocompromised Patients 56
Jun 05, 2012: Kaiser Permanente Study Shows GSK’s Zoster Lowers Short-Term Risk Of Shingles Recurrence 57
Dec 13, 2010: Inhibitex Reports Promising Top-Line Results From Phase II Shingles Trial With FV-100 58
Oct 15, 2010: Inhibitex Completes Enrollment In Phase II Clinical Trial Of FV-100 In Shingles Patients 59
Appendix 60
Methodology 60
Coverage 60
Secondary Research 60
Primary Research 60
Expert Panel Validation 60
Contact Us 60
Disclaimer 61

[List of Tables]
Number of Products under Development for Herpes Zoster (Shingles), H1 2015 8
Number of Products under Development for Herpes Zoster (Shingles) - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Comparative Analysis by Late Stage Development, H1 2015 11
Comparative Analysis by Clinical Stage Development, H1 2015 12
Comparative Analysis by Early Stage Development, H1 2015 13
Comparative Analysis by Unknown Stage Development, H1 2015 14
Products under Development by Companies, H1 2015 15
Herpes Zoster (Shingles) - Pipeline by Astellas Pharma Inc., H1 2015 16
Herpes Zoster (Shingles) - Pipeline by Epiphany Biosciences, Inc., H1 2015 17
Herpes Zoster (Shingles) - Pipeline by Foamix Pharmaceuticals Ltd., H1 2015 18
Herpes Zoster (Shingles) - Pipeline by GlaxoSmithKline plc, H1 2015 19
Herpes Zoster (Shingles) - Pipeline by Merck & Co., Inc., H1 2015 20
Herpes Zoster (Shingles) - Pipeline by NAL Pharmaceuticals Ltd., H1 2015 21
Herpes Zoster (Shingles) - Pipeline by Spider Biotech, H1 2015 22
Assessment by Monotherapy Products, H1 2015 23
Number of Products by Stage and Target, H1 2015 25
Number of Products by Stage and Mechanism of Action, H1 2015 27
Number of Products by Stage and Route of Administration, H1 2015 29
Number of Products by Stage and Molecule Type, H1 2015 31
Herpes Zoster (Shingles) Therapeutics - Recent Pipeline Updates, H1 2015 46
Herpes Zoster (Shingles) - Dormant Projects, H1 2015 50
Herpes Zoster (Shingles) - Discontinued Products, H1 2015 51

[List of Figures]
Number of Products under Development for Herpes Zoster (Shingles), H1 2015 8
Number of Products under Development for Herpes Zoster (Shingles) - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Comparative Analysis by Early Stage Products, H1 2015 13
Assessment by Monotherapy Products, H1 2015 23
Number of Products by Top 10 Targets, H1 2015 24
Number of Products by Stage and Top 10 Targets, H1 2015 25
Number of Products by Top 10 Mechanism of Actions, H1 2015 26
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 27
Number of Products by Top 10 Routes of Administration, H1 2015 28
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 29
Number of Products by Top 10 Molecule Types, H1 2015 30
Number of Products by Stage and Top 10 Molecule Types, H1 2015 31

【掲載企業】

Astellas Pharma Inc.
Epiphany Biosciences, Inc.
Foamix Pharmaceuticals Ltd.
GlaxoSmithKline plc
Merck & Co., Inc.
NAL Pharmaceuticals Ltd.
Spider Biotech

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 帯状ヘルペス(シングルス)(Herpes Zoster (Shingles)):治療薬開発パイプライン動向(2015年上半期版)(Herpes Zoster (Shingles) - Pipeline Review, H1 2015)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆